Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic…
A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion's personalized cancer vaccine, EVX-01, in patients with metastatic melanomaThe findings also demonstrate strong and clinically relevant immune responses after EVX-01 administration to metastatic melanoma patients co-treated with anti-PD-1 standard of care The clinical study results substantiate the precision and predictive power of Evaxion's AI-Immunology™...
Nasdaq GlobeNewswire
17/06/2024
PartitionBio™ awarded grant to exploit its novel biologics shuttle platform for…
PartitionBio™ is a Cambridge (UK) based biotech start-up company offering a revolutionary technology platform for the non-viral delivery of a broad spectrum of macromolecules with therapeutic potential across the cell membrane. Possible payloads for the shuttle condensates include antibodies, proteins, peptides and nucleic acids. PartitionBio ™ is aCambridge(UK) based biotech start-up company offering a revolutionary technology platform for the non-viral delivery of a broad spectrum of...
PR Newswire
17/06/2024
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 17 June 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…
Nasdaq GlobeNewswire
17/06/2024
Children's Tumor Foundation Presents the 2024 Global NF Conference in Brussels…
NF, encompassing neurofibromatosis type 1 (NF1), and all forms of schwannomatosis (SWN), including NF2-related schwannomatosis (NF2-SWN), affects approximately 4 million people worldwide. These genetic conditions cause tumors to grow on nerves throughout the body, leading to blindness, deafness, bone abnormalities, disfigurement, learning disabilities, disabling pain, and cancer. The Global NF Conference aims to redefine the future of NF research and care, accelerating the path to effective…
PR Newswire
17/06/2024
Multiple New Awards Recognize NCCN as Exceptional Source for Information for…
PLYMOUTH MEETING, Pa., June 17, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced new recognitions for the award-winning library of NCCN Guidelines for Patients® and NCCN Patient Webinars. The NCCN Guidelines for Patients: Colon Cancer earned a Gold Award from Hemes Creative Awards for Electronic Media/Social Media/Interactive Media/Digital Publications/Messaging. The NCCN Guidelines for Patients: Kidney Cancer earned an Award of Distinction from The…
PR Newswire
17/06/2024
Neuromod's FDA-Approved Lenire Device Now a Treatment Option for 2.9 Million US…
Lenire is the first bimodal neuromodulation device to receive a Federal Supply Schedule (FSS) Contract. It can be prescribed when appropriate by a trained healthcare clinician for the treatment of tinnitus. Lenire is the first bimodal neuromodulation device to receive a Federal Supply Schedule (FSS) Contract. It can be prescribed when appropriate by a trained healthcare clinician for the treatment of tinnitus. General Services Administration's decision to award the FSS contract was based on...
PR Newswire
17/06/2024
Zymeworks Announces FDA Clearance of Investigational New Drug Application for…
“We are excited to reach this R&D milestone with ZW171, reflecting our commitment to advancing innovative therapies for cancer treatment,” said Paul Moore, Chief Scientific Officer of Zymeworks. “ZW171's unique design is intended to address the limitations of current bispecific T-cell engagers by enhancing tumor selectivity and improving safety. With promising preclinical results, ZW171 has the potential to provide a more effective and tolerable treatment option for patients with...
Nasdaq GlobeNewswire
17/06/2024
ZINZINO AB (PUBL): LETTER OF INTENT TO ACQUIRE ZURVITA INCREASES DISTRIBUTION…
The business has total annual sales of approximately USD 30 million with good gross margins. The collaboration with Zinzino is expected to add growth through the synergies that arise in the joint networks, combined with Zinzino's test-based product concept. The profitability of the Company will thus be able to develop well by utilizing Zinzino's existing technical platform and organization. The business has total annual sales of approximatelyUSD 30 millionwith good gross margins. The...
PR Newswire
17/06/2024
Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of…
Company announcement, Helsinki, 17 June 2024 at 12:45 PM (EEST) Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) has received a notification pursuant to chapter 9, section 5 of the Securities Market Act from Leena Niemistö on 17 June 2024.The notification is based on the amendment to the Securities Market Act effective April 19, 2024, requiring shareholders to notify the...
Nasdaq GlobeNewswire
17/06/2024
Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for…
Professor Kouzarides has been dedicated to the conversion of science into patient benefit throughout his career. Professor Kouzarides has been dedicated to the conversion of science into patient benefit throughout his career. STORM Therapeutics was spun out from theUniversity of Cambridgein 2015 by Professor Kouzarides and his colleague ProfessorEric Miska, following their groundbreaking work in RNA epigenetics. Professor Kouzarides and his research group identified the importance of...
PR Newswire
17/06/2024
Funding secured for CE approval of the groundbreaking C-MIC device from Berlin…
To date, 35 C-MICs have been successfully implanted in a randomized study. The excellent data from a previous pilot study with 10 patients has now been confirmed. Accordingly, the company was able to raise a further CHF 10 million from new and existing investors in a recent financing round. This means that CE approval is financially secured and the next steps for US approval can be initiated. These funds will also be used to initiate the first studies in the USA. To date, 35 C-MICs have been...
PR Newswire
17/06/2024
Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in…
In the intention-to-treat population (118 participants), safety and tolerability were not significantly different between groups. In the secondary outcomes, MUNIX showed a significantly reduced decline with Fasudil 60 mg at 26 and 90 days, and for Fasudil 30 mg at 90 days after treatment initiation. In addition, there was a directional difference in a slower loss of SVC favoring the 60 mg of fasudil treatment at day 26, which was statistically significant in a post-hoc subgroup analysis of…
PR Newswire
17/06/2024
Essity decides to buy back shares for SEK 3bn
The share buyback program will be managed by Danske Bank, which will decide on the date for repurchasing independently from and outside of Essity's influence. Repurchasing will take place on Nasdaq Stockholm in accordance with the stock exchange's issuer regulations and be implemented in accordance with the EU Market Abuse Regulation (MAR) and the European Commission's Delegated Regulation 2016/1052 (Safe Harbour Regulation). The share buyback program will be managed by Danske Bank, which...
PR Newswire
17/06/2024
Essity presents new financial targets
Annual organic sales growth >3% Essity's new target is annual organic sales growth of more than 3%. The previous target was an annual sales growth of more than 5%, which included organic sales growth of more than 3% and acquisitions of approximately 2%. Acquisitions remain part of the company's strategy but are no longer included in the annual growth target. Annual organic sales growth >3% Essity's new target is annual organic sales growth of more than 3%. The previous target was an...
PR Newswire
17/06/2024
XRP Healthcare Magazine Issue 3: Featuring Ugandan Innovator Peter Waiswa, NHS…
"I'm involved with XRP Healthcare because I admire their commitment to improving the quality and capacity of healthcare in Uganda. Currently, our healthcare system is fragmented, mostly privatised, and often lacks regulation. Despite this, we face complex health challenges. Investing in healthcare in Uganda and Africa holds great promise because the market is growing along with demand." "I'm involved with XRP Healthcare because I admire their commitment to improving the quality…
PR Newswire
17/06/2024
Casio to Release G-SHOCK with Workout Logs and More Comfortable Fit
The G-SHOCK first came out in 1983, delivering on a passion to create a tough watch that would not break even if dropped. Ever since, Casio has continued to introduce functional, structural, and design advancements to the brand's outstanding shock resistance. Stacked with data-tracking functions, the sports-driven G-SQUAD line in the G-SHOCK brand has proven very popular. The G-SHOCK first came out in 1983, delivering on a passion to create a tough watch that would not break even if dropped...
PR Newswire
17/06/2024
Roche's Phase III STARGLO study demonstrates Columvi significantly extends…
The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy 1 This Columvi combination could provide a much-needed off-the-shelf treatment option for people with transplant-ineligible R/R DLBCLData were featured in the congress Press Briefing and presented today in the Plenary Abstracts Session at EHA 2024 as a late-breaking...
Nasdaq GlobeNewswire
15/06/2024
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in…
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress. Galapagos' product candidate GLPG5101 is produced using the company's innovative, decentralized T-cell manufacturing platform.The oral...
Nasdaq GlobeNewswire
14/06/2024
Casino completes reverse share split Adjustments to the warrants exercise parity…
Casino completes reverse share splitAdjustments to the warrants exercise parity and allocation rights under free share allocation plans Paris, 14 June 2024Casino, Guichard-Perrachon (“ Casino ”) today announces (i) the completion of the reverse share split of its share capital through the exchange of one hundred (100) existing shares for one (1) new share and (ii) the effectiveness of the share capital reduction through a decrease in the par value of the shares decided by Casino's...
Nasdaq GlobeNewswire
14/06/2024
Medical Equipment Maintenance Market: Forecasted USD 88.9 Billion by 2029, CAGR…
Browse in-depth TOC on "Medical Equipment Maintenance Market" Browse in-depth TOC on "Medical Equipment Maintenance Market" 307 - Tables 58 - Figures 362 - Pages Industry Dynamics: Growth Drivers in Medical Equipment Maintenance Growth in Medical Equipment Markets:The global expansion of various medical equipment markets is fueled by the need for safer, more efficient, and higher-quality healthcare. Innovations in the sector further drive this growth, with patients...
PR Newswire
14/06/2024
Renovaro, Inc. Announces $10 million in Equity Committed
“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO. “We believe this is only the beginning. We are hopeful to be able to secure additional financing such as, but not limited to, long-term loans, grants and subsidies from various US and European institutions for which the Company is eligible – potentially worth tens of millions of dollars.” Forward-Looking Statements Statements in this press release that are not strictly historical...
Nasdaq GlobeNewswire
14/06/2024
UN OFFICIALS VISIT HUMAN APPEAL PROJECT FOR 1500 FAMIILIES IN NORTHWEST SYRIA
So far 1,500 temporary dignified shelters have been constructed in Al Yasameen IDP site for Syrian families displaced by conflict. The project also recently installed a water well and a water tank in each shelter to support the families that will move in. The light-briquette dignified shelters are specifically designed for families and offer much better protection than typical tent shelters, especially during harsh winter and summer weather conditions. So far 1,500 temporary dignified…
PR Newswire
14/06/2024
ElmediX Plans Series A Round Based on Strong Signals in a Clinical Study for…
A novel and innovative approach to treating metastasized cancer, starting with the very lethal grade 4 pancreatic cancer. Earlier this year, scientists from Columbia University in New York demonstrated that the growth rate of pancreatic cancer, measured in patients' blood using CA19-9 as biomarker, determines survival chances and can be used as a quick way to assess treatment effectiveness. At the end of a treatment cycle, both the patient and the treating physician have a clear view of the...
Nasdaq GlobeNewswire
14/06/2024
IQ Medical Ventures rebrands as IQ Women's Health to pioneer innovations in…
IQ Women's Health is dedicated to fostering innovation and supporting the development of cutting-edge solutions in women's health. The organization caters to the needs of physicians, start-ups, and investors, providing the resources, network, and regulatory guidance necessary to succeed in advancing women's health outcomes worldwide. IQ Women's Health is dedicated to fostering innovation and supporting the development of cutting-edge solutions in women's health. The organization caters to the...
PR Newswire
14/06/2024
Altri Comunicati
